Get started
Coherus BioSciences, Inc.Coherus BioSciences, Inc.Coherus BioSciences, Inc.

Coherus BioSciences, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

CHRS chart


Full chart

CHRS upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪93.90 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.0079 USD
Net income (FY)
‪−237.89 M‬ USD
Revenue (FY)
‪257.24 M‬ USD
Shares float
‪110.58 M‬
Beta (1Y)
1.25

Employees


Employees (FY)
306
Change (1Y)
−53 −14.76%
Revenue / Employee (1Y)
‪840.67 K‬ USD
Net income / Employee (1Y)
‪−777.42 K‬ USD

About Coherus BioSciences, Inc.


Sector
Health Technology
CEO
Denny M. Lanfear
Headquarters
Redwood City
Website
coherus.com
Founded
2010
FIGI
BBG0063N8V69
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and Coherus COMPLETE. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

CHRS news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

CHRS highest yielding bonds


CHRS5172388
Coherus BioSciences, Inc. 1.5% 15-APR-2026
Yield to maturity
17.38%
Maturity date
Apr 15, 2026

Explore more bonds 

Frequently Asked Questions


The current price of CHRS is 0.8150 USD — it has decreased by −0.61% in the past 24 hours. Watch Coherus BioSciences, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Coherus BioSciences, Inc. stocks are traded under the ticker CHRS.
CHRS stock has risen by 9.40% compared to the previous week, the month change is a −21.63% fall, over the last year Coherus BioSciences, Inc. has showed a −60.05% decrease.
We've gathered analysts' opinions on Coherus BioSciences, Inc. future price: according to them, CHRS price has a max estimate of 12.00 USD and a min estimate of 1.50 USD. Watch CHRS chart and read a more detailed Coherus BioSciences, Inc. stock forecast: see what analysts think of Coherus BioSciences, Inc. and suggest that you do with its stocks.
CHRS reached its all-time high on Jul 22, 2015 with the price of 38.1000 USD, and its all-time low was 0.7100 USD and was reached on Oct 29, 2024. View more price dynamics on CHRS chart.
See other stocks reaching their highest and lowest prices.
CHRS stock is 11.49% volatile and has beta coefficient of 1.25. Track Coherus BioSciences, Inc. stock price on the chart and check out the list of the most volatile stocks — is Coherus BioSciences, Inc. there?
Today Coherus BioSciences, Inc. has the market capitalization of ‪93.90 M‬, it has decreased by −5.57% over the last week.
Yes, you can track Coherus BioSciences, Inc. financials in yearly and quarterly reports right on TradingView.
Coherus BioSciences, Inc. is going to release the next earnings report on Feb 27, 2025. Keep track of upcoming events with our Earnings Calendar.
CHRS earnings for the last quarter are −0.09 USD per share, whereas the estimation was −0.16 USD resulting in a 44.91% surprise. The estimated earnings for the next quarter are −0.27 USD per share. See more details about Coherus BioSciences, Inc. earnings.
Coherus BioSciences, Inc. revenue for the last quarter amounts to ‪70.77 M‬ USD, despite the estimated figure of ‪58.98 M‬ USD. In the next quarter, revenue is expected to reach ‪50.61 M‬ USD.
CHRS net income for the last quarter is ‪−10.75 M‬ USD, while the quarter before that showed ‪−12.92 M‬ USD of net income which accounts for 16.79% change. Track more Coherus BioSciences, Inc. financial stats to get the full picture.
No, CHRS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 10, 2024, the company has 306.00 employees. See our rating of the largest employees — is Coherus BioSciences, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Coherus BioSciences, Inc. EBITDA is ‪−125.67 M‬ USD, and current EBITDA margin is −73.63%. See more stats in Coherus BioSciences, Inc. financial statements.
Like other stocks, CHRS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Coherus BioSciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Coherus BioSciences, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Coherus BioSciences, Inc. stock shows the sell signal. See more of Coherus BioSciences, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.